Dr. Donald Lee Durden MD Pediatric Hematologist-Oncologist

Dr. Donald Durden is a pediatric hematologist-oncologist in San Diego, California. He received his medical degree from University of Miami Miller School of Medicine and has been in practice for 29 years. Dr. Durden accepts several types of health insurance, listed below.

Are you Dr. Durden? Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Pediatric Hematologist-Oncologist: General Pediatric Hematology & Oncology

Education & Medical Training

St Christophers Hospital Children's
Residency, Pediatrics, 1985–1987

University of Washington
Residency, Pediatrics, 1987–1988

University of Washington
Fellowship, Pediatric Hematology/Oncology, 1988–1993

University of Miami Miller School of Medicine
Class of 1985

University of Miami School of Medicine
Other Training, 1981–1982

University of South Florida
Other Training, Microbiology and Zoology, 1971–1977

University of Miami School of Medicine
Other Training, 1981–1982

Certifications & Licensure

Pediatric Hematology-Oncology
Certified 4 years in Pediatric Hematology-Oncology

American Board of Pediatrics
Certified in Pediatrics

CA State Medical License
Active through 2015

Awards, Honors & Recognition

Cancer Working Group, USWNR
2012

Goldhirsh Foundation Award
2007

Aflac Endowed Professo, Emory University School of Medicine
2004

Distinguished Cancer Scholar Award, Georgia Cancer Coalition
2003

Society for Pediatric Research
1997

Stop Cancer Research Career Development Award
1997

National Research Service Award, National Institutes of Health
1989

American Cancer Society Postdoctoral Fellowship
1988

Sigma Xi
1979

Publications & Presentations

PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
Muh, C. R.,Joshi, S.,Singh, A. R.,Kesari, S.,Durden, D. L.,Makale, M. T.

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors.
Morales, G. A.,Garlich, J. R.,Su, J.,Peng, X.,Newblom, J.,Weber, K.,Durden, D. L.

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De, P.,Dey, N.,Terakedis, B.,Bergsagel, P. L.,Li, Z. H.,Mahadevan, D.,Garlich, J. R.,Trudel, S.,Makale, M. T.,Durden, D. L.

See all 56 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS California CaliforniaCare HMO
  • BCBS California PowerSelect HMO
  • BCBS California PPO
  • Blue Shield CA Local Access Plus HMO
  • Blue Shield California HMO
  • Blue Shield California PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • Pacificare HMO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support


See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Pediatric Hematologist-Oncologists

See all Pediatric Hematologist-Oncologists near San Diego, CA See all Pediatric Hematologist-Oncologists in California

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.